Common use of Designated Manufacturer Agreements for Clinical Supply Clause in Contracts

Designated Manufacturer Agreements for Clinical Supply. Subject to oversight by the JSC, the Parties shall be jointly responsible for procuring sufficient quantities of Collaboration Compound and Collaboration Product as are necessary for the Parties to perform their respective obligations under the Development Plan. Unless the Parties agree to a single Designated Manufacturer under Section 4.4.1, Xxxxxxxxx shall negotiate in good faith and enter into an agreement with a Designated Manufacturer for the Manufacture and supply of such quantities of Collaboration Compound and Collaboration Product as are necessary for Xxxxxxxxx to perform its obligations under the Development Plan (i.e., with respect to China). In the case where such agreement refers to the future commercial terms of supply of a Collaboration Compound or Collaboration Product then the prior approval of AstraZeneca to such terms shall be sought. Unless the Parties agree to a single Designated Manufacturer under Section 4.4.1, AstraZeneca shall negotiate in good faith and enter into an agreement with a Designated Manufacturer for the Manufacture and supply of such quantities of Collaboration Compound and Collaboration Product as are necessary for AstraZeneca to perform its obligations under the Development Plan (i.e., with respect to the ROW Territory). Each Party shall promptly provide to the other Party a copy of its agreement with the Designated Manufacturer promptly after execution thereof. [**]. The Parties shall share costs and expenses of procuring supply from a Designated Manufacturer under this Section 4.4.2 in accordance with the allocations set forth in Section 5.7.

Designated Manufacturer Agreements for Clinical Supply. Subject to oversight by the JSC, the Parties shall be jointly responsible for procuring sufficient quantities of Collaboration Compound and Collaboration Product as are necessary for the Parties to perform their respective obligations under the Development Plan. Unless the Parties agree to a single Designated Manufacturer under Section 4.4.1, Xxxxxxxxx shall (x) negotiate in good faith and enter into an agreement with a Designated Manufacturer for the Manufacture and supply of such quantities of Collaboration Compound and Collaboration Product as are necessary for Xxxxxxxxx to perform its obligations under the Development Plan (i.e., with respect to China) or (y) with AstraZeneca’s prior approval (not to be unreasonably withheld, delayed or conditioned), Manufacture and supply such quantities of Collaboration Compound and Collaboration Product itself or through an Affiliate. In the case where such agreement refers to the future commercial terms of supply of a Collaboration Compound or Collaboration Product then the prior approval of AstraZeneca to such terms shall be sought. Unless the Parties agree to a single Designated Manufacturer under Section 4.4.1, AstraZeneca shall negotiate in good faith and enter into an agreement with a Designated Manufacturer for the Manufacture and supply of such quantities of Collaboration Compound and Collaboration Product as are necessary for AstraZeneca to perform its obligations under the Development Plan (i.e., with respect to the ROW Territory). Each Party shall promptly provide to the other Party a copy of its agreement with the Designated Manufacturer promptly after execution thereof. [**]. The Parties shall share costs and expenses of procuring supply from a Designated Manufacturer under this Section 4.4.2 in accordance with the allocations set forth in Section 5.7.. ​